The Australian Health Manufacturers and Development Association (AHMADA) welcomed the launch of the new medication, MAXIGESIC®, which reduces pain and inflammation.
According to the media release by AHMADA, MAXIGESIC® uses two active pain ingredients (Paracetamol 500 mg and Ibuprofen 150 mg) in a specific formulation without codeine.
The medication was developed and patented by privately-owned Australasian pharmaceutical company called AFT Pharmaceuticals, which is a founding member of AHMADA.
The company was sold in New Zealand in 2009 and has since licensed Maxigesic® for sale in more than 40 countries across the world, including Australia, where it is now available as a Schedule 3 (S3) Pharmacist-Only Medicine.
AFT Pharmaceuticals has over 20 products listed on Australia’s Pharmaceutical Benefits Scheme (PBS) and sells medicines in more than 1,000 public and private hospitals across Australia.
AHMADA President, Dr Mal Eutick, congratulated the company on the launch of MAXIGESIC® in the Australian market saying it demonstrates how local pharmaceutical companies are driving the commercialisation of innovative research and development.
“This is a great example of how AFT Pharmaceuticals has committed to ongoing local research and innovation, importantly bringing MAXIGESIC® to market in both Australia and New Zealand with other international markets to follow,” Dr Eutick said.
“It’s a home-grown medicine which will not only benefit health consumers across Australasia, but the local economy, in the form of skill development and employment for researchers and scientists.”
AHMADA members are Australian and New Zealand companies which place a strong emphasis on research and investment in local skill development and jobs. The association has been specifically created to represent the interests of Australia and New Zealand companies in the health manufacture and development sector.
